HighVista Strategies LLC Has $1.87 Million Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

HighVista Strategies LLC cut its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 15.8% during the third quarter, HoldingsChannel.com reports. The firm owned 74,639 shares of the company’s stock after selling 14,049 shares during the period. HighVista Strategies LLC’s holdings in Kiniksa Pharmaceuticals were worth $1,865,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. CWM LLC grew its holdings in shares of Kiniksa Pharmaceuticals by 443.0% during the 3rd quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $61,000 after acquiring an additional 1,998 shares in the last quarter. nVerses Capital LLC purchased a new position in Kiniksa Pharmaceuticals in the third quarter valued at about $80,000. Lazard Asset Management LLC acquired a new position in Kiniksa Pharmaceuticals in the 1st quarter worth about $71,000. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Kiniksa Pharmaceuticals during the 2nd quarter worth about $100,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter valued at about $189,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Kiniksa Pharmaceuticals

In other news, COO Eben Tessari sold 17,500 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $24.99, for a total transaction of $437,325.00. Following the sale, the chief operating officer now directly owns 116,975 shares in the company, valued at approximately $2,923,205.25. The trade was a 13.01 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 54.57% of the company’s stock.

Kiniksa Pharmaceuticals Price Performance

NASDAQ:KNSA opened at $21.85 on Tuesday. Kiniksa Pharmaceuticals, Ltd. has a one year low of $16.47 and a one year high of $28.15. The company has a fifty day moving average price of $23.95 and a 200 day moving average price of $22.98. The stock has a market cap of $1.58 billion, a P/E ratio of -156.06 and a beta of 0.27.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, October 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company had revenue of $112.21 million for the quarter, compared to the consensus estimate of $111.51 million. During the same quarter in the previous year, the firm posted ($0.20) EPS. The business’s revenue for the quarter was up 67.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Evercore ISI lifted their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Jefferies Financial Group began coverage on Kiniksa Pharmaceuticals in a report on Friday, September 13th. They set a “buy” rating and a $40.00 target price on the stock. Finally, JPMorgan Chase & Co. raised their price objective on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $36.60.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.